Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Identifieur interne : 000127 ( Main/Exploration ); précédent : 000126; suivant : 000128Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Auteurs : Michele Maio [Italie] ; Arnaud Scherpereel [France] ; Luana Calabr [Italie] ; Joachim Aerts [Pays-Bas] ; Susana Cedres Perez [Espagne] ; Alessandra Bearz [Italie] ; Kristiaan Nackaerts [Belgique] ; Dean A. Fennell [Royaume-Uni] ; Dariusz Kowalski [Pologne] ; Anne S. Tsao [États-Unis] ; Paul Taylor [Royaume-Uni] ; Federica Grosso [Italie] ; Scott J. Antonia [États-Unis] ; Anna K. Nowak [Australie] ; Maria Taboada [Royaume-Uni] ; Martina Puglisi [Royaume-Uni] ; Paul K. Stockman [Royaume-Uni] ; Hedy L. Kindler [États-Unis]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Critères d'évaluation de la réponse dans les tumeurs solides, Femelle, Humains, Mâle, Mésothéliome (anatomopathologie), Mésothéliome (mortalité), Mésothéliome (traitement médicamenteux), Méthode en double aveugle, Résultat thérapeutique, Sujet âgé, Survie sans rechute, Taux de survie, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (mortalité), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- anatomopathologie : Mésothéliome, Tumeurs du poumon.
- mortalité : Mésothéliome, Tumeurs du poumon.
- traitement médicamenteux : Mésothéliome, Tumeurs du poumon.
- usage thérapeutique : Anticorps monoclonaux, Antinéoplasiques.
- Adulte d'âge moyen, Critères d'évaluation de la réponse dans les tumeurs solides, Femelle, Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé, Survie sans rechute, Taux de survie.
English descriptors
- KwdEn :
- Aged, Antibodies, Monoclonal (therapeutic use), Antineoplastic Agents (therapeutic use), Disease-Free Survival, Double-Blind Method, Female, Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Male, Mesothelioma (drug therapy), Mesothelioma (mortality), Mesothelioma (pathology), Middle Aged, Response Evaluation Criteria in Solid Tumors, Survival Rate, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Antineoplastic Agents.
- drug therapy : Lung Neoplasms, Mesothelioma.
- mortality : Lung Neoplasms, Mesothelioma.
- pathology : Lung Neoplasms, Mesothelioma.
- Aged, Disease-Free Survival, Double-Blind Method, Female, Humans, Male, Middle Aged, Response Evaluation Criteria in Solid Tumors, Survival Rate, Treatment Outcome.
Abstract
New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.
DOI: 10.1016/S1470-2045(17)30446-1
PubMed: 28729154
Affiliations:
- Australie, Belgique, Espagne, France, Italie, Pays-Bas, Pologne, Royaume-Uni, États-Unis
- Angleterre, Catalogne, Floride, Grand Manchester, Hauts-de-France, Hollande-Méridionale, Illinois, Nord-Pas-de-Calais, Texas
- Barcelone, Lille, Manchester, Rotterdam
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000534
- to stream PubMed, to step Curation: 000532
- to stream PubMed, to step Checkpoint: 000532
- to stream Ncbi, to step Merge: 004B55
- to stream Ncbi, to step Curation: 004B55
- to stream Ncbi, to step Checkpoint: 004B55
- to stream Main, to step Merge: 000122
- to stream Main, to step Curation: 000127
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.</title><author><name sortKey="Maio, Michele" sort="Maio, Michele" uniqKey="Maio M" first="Michele" last="Maio">Michele Maio</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address: mmaiocro@gmail.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Scherpereel, Arnaud" sort="Scherpereel, Arnaud" uniqKey="Scherpereel A" first="Arnaud" last="Scherpereel">Arnaud Scherpereel</name><affiliation wicri:level="3"><nlm:affiliation>Pulmonary and Thoracic Oncology, University of Lille, CHU de Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pulmonary and Thoracic Oncology, University of Lille, CHU de Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Calabr, Luana" sort="Calabr, Luana" uniqKey="Calabr L" first="Luana" last="Calabr">Luana Calabr</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Aerts, Joachim" sort="Aerts, Joachim" uniqKey="Aerts J" first="Joachim" last="Aerts">Joachim Aerts</name><affiliation wicri:level="3"><nlm:affiliation>Erasmus Medical Center, Rotterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Erasmus Medical Center, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Perez, Susana Cedres" sort="Perez, Susana Cedres" uniqKey="Perez S" first="Susana Cedres" last="Perez">Susana Cedres Perez</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron Institute of Oncology, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Bearz, Alessandra" sort="Bearz, Alessandra" uniqKey="Bearz A" first="Alessandra" last="Bearz">Alessandra Bearz</name><affiliation wicri:level="1"><nlm:affiliation>Centro di Riferimento Oncologico di Aviano, Pordenone, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Centro di Riferimento Oncologico di Aviano, Pordenone</wicri:regionArea><wicri:noRegion>Pordenone</wicri:noRegion></affiliation></author><author><name sortKey="Nackaerts, Kristiaan" sort="Nackaerts, Kristiaan" uniqKey="Nackaerts K" first="Kristiaan" last="Nackaerts">Kristiaan Nackaerts</name><affiliation wicri:level="1"><nlm:affiliation>KU Leuven-University of Leuven, University Hospitals, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>KU Leuven-University of Leuven, University Hospitals, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Fennell, Dean A" sort="Fennell, Dean A" uniqKey="Fennell D" first="Dean A" last="Fennell">Dean A. Fennell</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals of Leicester, Leicester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Hospitals of Leicester, Leicester</wicri:regionArea><wicri:noRegion>Leicester</wicri:noRegion></affiliation></author><author><name sortKey="Kowalski, Dariusz" sort="Kowalski, Dariusz" uniqKey="Kowalski D" first="Dariusz" last="Kowalski">Dariusz Kowalski</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Tsao, Anne S" sort="Tsao, Anne S" uniqKey="Tsao A" first="Anne S" last="Tsao">Anne S. Tsao</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Taylor, Paul" sort="Taylor, Paul" uniqKey="Taylor P" first="Paul" last="Taylor">Paul Taylor</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital of South Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Hospital of South Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Grosso, Federica" sort="Grosso, Federica" uniqKey="Grosso F" first="Federica" last="Grosso">Federica Grosso</name><affiliation wicri:level="1"><nlm:affiliation>Mesothelioma Unit-Medical Oncology Department, SS Antonio e Biagio General Hospital, Alessandria, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mesothelioma Unit-Medical Oncology Department, SS Antonio e Biagio General Hospital, Alessandria</wicri:regionArea><wicri:noRegion>Alessandria</wicri:noRegion></affiliation></author><author><name sortKey="Antonia, Scott J" sort="Antonia, Scott J" uniqKey="Antonia S" first="Scott J" last="Antonia">Scott J. Antonia</name><affiliation wicri:level="2"><nlm:affiliation>H Lee Moffitt Cancer Center, Tampa, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>H Lee Moffitt Cancer Center, Tampa, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Nowak, Anna K" sort="Nowak, Anna K" uniqKey="Nowak A" first="Anna K" last="Nowak">Anna K. Nowak</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Taboada, Maria" sort="Taboada, Maria" uniqKey="Taboada M" first="Maria" last="Taboada">Maria Taboada</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Alderley Park, Macclesfield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Alderley Park, Macclesfield</wicri:regionArea><wicri:noRegion>Macclesfield</wicri:noRegion></affiliation></author><author><name sortKey="Puglisi, Martina" sort="Puglisi, Martina" uniqKey="Puglisi M" first="Martina" last="Puglisi">Martina Puglisi</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Stockman, Paul K" sort="Stockman, Paul K" uniqKey="Stockman P" first="Paul K" last="Stockman">Paul K. Stockman</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Alderley Park, Macclesfield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Alderley Park, Macclesfield</wicri:regionArea><wicri:noRegion>Macclesfield</wicri:noRegion></affiliation></author><author><name sortKey="Kindler, Hedy L" sort="Kindler, Hedy L" uniqKey="Kindler H" first="Hedy L" last="Kindler">Hedy L. Kindler</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Chicago, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Chicago, Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28729154</idno><idno type="pmid">28729154</idno><idno type="doi">10.1016/S1470-2045(17)30446-1</idno><idno type="wicri:Area/PubMed/Corpus">000534</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000534</idno><idno type="wicri:Area/PubMed/Curation">000532</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000532</idno><idno type="wicri:Area/PubMed/Checkpoint">000532</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000532</idno><idno type="wicri:Area/Ncbi/Merge">004B55</idno><idno type="wicri:Area/Ncbi/Curation">004B55</idno><idno type="wicri:Area/Ncbi/Checkpoint">004B55</idno><idno type="wicri:Area/Main/Merge">000122</idno><idno type="wicri:Area/Main/Curation">000127</idno><idno type="wicri:Area/Main/Exploration">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.</title><author><name sortKey="Maio, Michele" sort="Maio, Michele" uniqKey="Maio M" first="Michele" last="Maio">Michele Maio</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Electronic address: mmaiocro@gmail.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Scherpereel, Arnaud" sort="Scherpereel, Arnaud" uniqKey="Scherpereel A" first="Arnaud" last="Scherpereel">Arnaud Scherpereel</name><affiliation wicri:level="3"><nlm:affiliation>Pulmonary and Thoracic Oncology, University of Lille, CHU de Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pulmonary and Thoracic Oncology, University of Lille, CHU de Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Calabr, Luana" sort="Calabr, Luana" uniqKey="Calabr L" first="Luana" last="Calabr">Luana Calabr</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Medical Oncology and Immunotherapy, Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena</wicri:regionArea><wicri:noRegion>Siena</wicri:noRegion></affiliation></author><author><name sortKey="Aerts, Joachim" sort="Aerts, Joachim" uniqKey="Aerts J" first="Joachim" last="Aerts">Joachim Aerts</name><affiliation wicri:level="3"><nlm:affiliation>Erasmus Medical Center, Rotterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Erasmus Medical Center, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Perez, Susana Cedres" sort="Perez, Susana Cedres" uniqKey="Perez S" first="Susana Cedres" last="Perez">Susana Cedres Perez</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron Institute of Oncology, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Bearz, Alessandra" sort="Bearz, Alessandra" uniqKey="Bearz A" first="Alessandra" last="Bearz">Alessandra Bearz</name><affiliation wicri:level="1"><nlm:affiliation>Centro di Riferimento Oncologico di Aviano, Pordenone, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Centro di Riferimento Oncologico di Aviano, Pordenone</wicri:regionArea><wicri:noRegion>Pordenone</wicri:noRegion></affiliation></author><author><name sortKey="Nackaerts, Kristiaan" sort="Nackaerts, Kristiaan" uniqKey="Nackaerts K" first="Kristiaan" last="Nackaerts">Kristiaan Nackaerts</name><affiliation wicri:level="1"><nlm:affiliation>KU Leuven-University of Leuven, University Hospitals, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>KU Leuven-University of Leuven, University Hospitals, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Fennell, Dean A" sort="Fennell, Dean A" uniqKey="Fennell D" first="Dean A" last="Fennell">Dean A. Fennell</name><affiliation wicri:level="1"><nlm:affiliation>University Hospitals of Leicester, Leicester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Hospitals of Leicester, Leicester</wicri:regionArea><wicri:noRegion>Leicester</wicri:noRegion></affiliation></author><author><name sortKey="Kowalski, Dariusz" sort="Kowalski, Dariusz" uniqKey="Kowalski D" first="Dariusz" last="Kowalski">Dariusz Kowalski</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Tsao, Anne S" sort="Tsao, Anne S" uniqKey="Tsao A" first="Anne S" last="Tsao">Anne S. Tsao</name><affiliation wicri:level="2"><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>The University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Taylor, Paul" sort="Taylor, Paul" uniqKey="Taylor P" first="Paul" last="Taylor">Paul Taylor</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital of South Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Hospital of South Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Grosso, Federica" sort="Grosso, Federica" uniqKey="Grosso F" first="Federica" last="Grosso">Federica Grosso</name><affiliation wicri:level="1"><nlm:affiliation>Mesothelioma Unit-Medical Oncology Department, SS Antonio e Biagio General Hospital, Alessandria, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Mesothelioma Unit-Medical Oncology Department, SS Antonio e Biagio General Hospital, Alessandria</wicri:regionArea><wicri:noRegion>Alessandria</wicri:noRegion></affiliation></author><author><name sortKey="Antonia, Scott J" sort="Antonia, Scott J" uniqKey="Antonia S" first="Scott J" last="Antonia">Scott J. Antonia</name><affiliation wicri:level="2"><nlm:affiliation>H Lee Moffitt Cancer Center, Tampa, FL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>H Lee Moffitt Cancer Center, Tampa, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Nowak, Anna K" sort="Nowak, Anna K" uniqKey="Nowak A" first="Anna K" last="Nowak">Anna K. Nowak</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Taboada, Maria" sort="Taboada, Maria" uniqKey="Taboada M" first="Maria" last="Taboada">Maria Taboada</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Alderley Park, Macclesfield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Alderley Park, Macclesfield</wicri:regionArea><wicri:noRegion>Macclesfield</wicri:noRegion></affiliation></author><author><name sortKey="Puglisi, Martina" sort="Puglisi, Martina" uniqKey="Puglisi M" first="Martina" last="Puglisi">Martina Puglisi</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Stockman, Paul K" sort="Stockman, Paul K" uniqKey="Stockman P" first="Paul K" last="Stockman">Paul K. Stockman</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Alderley Park, Macclesfield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Alderley Park, Macclesfield</wicri:regionArea><wicri:noRegion>Macclesfield</wicri:noRegion></affiliation></author><author><name sortKey="Kindler, Hedy L" sort="Kindler, Hedy L" uniqKey="Kindler H" first="Hedy L" last="Kindler">Hedy L. Kindler</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Chicago, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Chicago, Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (mortality)</term><term>Lung Neoplasms (pathology)</term><term>Male</term><term>Mesothelioma (drug therapy)</term><term>Mesothelioma (mortality)</term><term>Mesothelioma (pathology)</term><term>Middle Aged</term><term>Response Evaluation Criteria in Solid Tumors</term><term>Survival Rate</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Critères d'évaluation de la réponse dans les tumeurs solides</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Mésothéliome (anatomopathologie)</term><term>Mésothéliome (mortalité)</term><term>Mésothéliome (traitement médicamenteux)</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (mortalité)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mésothéliome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term><term>Mesothelioma</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lung Neoplasms</term><term>Mesothelioma</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Mésothéliome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term><term>Mesothelioma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mésothéliome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Response Evaluation Criteria in Solid Tumors</term><term>Survival Rate</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Critères d'évaluation de la réponse dans les tumeurs solides</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Taux de survie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Catalogne</li><li>Floride</li><li>Grand Manchester</li><li>Hauts-de-France</li><li>Hollande-Méridionale</li><li>Illinois</li><li>Nord-Pas-de-Calais</li><li>Texas</li></region><settlement><li>Barcelone</li><li>Lille</li><li>Manchester</li><li>Rotterdam</li></settlement></list><tree><country name="Italie"><noRegion><name sortKey="Maio, Michele" sort="Maio, Michele" uniqKey="Maio M" first="Michele" last="Maio">Michele Maio</name></noRegion><name sortKey="Bearz, Alessandra" sort="Bearz, Alessandra" uniqKey="Bearz A" first="Alessandra" last="Bearz">Alessandra Bearz</name><name sortKey="Calabr, Luana" sort="Calabr, Luana" uniqKey="Calabr L" first="Luana" last="Calabr">Luana Calabr</name><name sortKey="Grosso, Federica" sort="Grosso, Federica" uniqKey="Grosso F" first="Federica" last="Grosso">Federica Grosso</name></country><country name="France"><region name="Hauts-de-France"><name sortKey="Scherpereel, Arnaud" sort="Scherpereel, Arnaud" uniqKey="Scherpereel A" first="Arnaud" last="Scherpereel">Arnaud Scherpereel</name></region></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Aerts, Joachim" sort="Aerts, Joachim" uniqKey="Aerts J" first="Joachim" last="Aerts">Joachim Aerts</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Perez, Susana Cedres" sort="Perez, Susana Cedres" uniqKey="Perez S" first="Susana Cedres" last="Perez">Susana Cedres Perez</name></region></country><country name="Belgique"><noRegion><name sortKey="Nackaerts, Kristiaan" sort="Nackaerts, Kristiaan" uniqKey="Nackaerts K" first="Kristiaan" last="Nackaerts">Kristiaan Nackaerts</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Fennell, Dean A" sort="Fennell, Dean A" uniqKey="Fennell D" first="Dean A" last="Fennell">Dean A. Fennell</name></noRegion><name sortKey="Puglisi, Martina" sort="Puglisi, Martina" uniqKey="Puglisi M" first="Martina" last="Puglisi">Martina Puglisi</name><name sortKey="Stockman, Paul K" sort="Stockman, Paul K" uniqKey="Stockman P" first="Paul K" last="Stockman">Paul K. Stockman</name><name sortKey="Taboada, Maria" sort="Taboada, Maria" uniqKey="Taboada M" first="Maria" last="Taboada">Maria Taboada</name><name sortKey="Taylor, Paul" sort="Taylor, Paul" uniqKey="Taylor P" first="Paul" last="Taylor">Paul Taylor</name></country><country name="Pologne"><noRegion><name sortKey="Kowalski, Dariusz" sort="Kowalski, Dariusz" uniqKey="Kowalski D" first="Dariusz" last="Kowalski">Dariusz Kowalski</name></noRegion></country><country name="États-Unis"><region name="Texas"><name sortKey="Tsao, Anne S" sort="Tsao, Anne S" uniqKey="Tsao A" first="Anne S" last="Tsao">Anne S. Tsao</name></region><name sortKey="Antonia, Scott J" sort="Antonia, Scott J" uniqKey="Antonia S" first="Scott J" last="Antonia">Scott J. Antonia</name><name sortKey="Kindler, Hedy L" sort="Kindler, Hedy L" uniqKey="Kindler H" first="Hedy L" last="Kindler">Hedy L. Kindler</name></country><country name="Australie"><noRegion><name sortKey="Nowak, Anna K" sort="Nowak, Anna K" uniqKey="Nowak A" first="Anna K" last="Nowak">Anna K. Nowak</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28729154
|texte= Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28729154" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |